Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Date:3/12/2009

PALO ALTO, Calif., March 12 /PRNewswire-FirstCall/ -- The Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that after careful consideration of Astellas Pharma Inc.'s $16.00 per share cash offer with its independent financial and legal advisors, it has determined that Astellas' offer undervalues the Company and is not in the best interests of its stockholders. Accordingly, the Board of Directors recommends that stockholders not tender any of their shares into the Astellas tender offer.

The Company is filing with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Additional Information

In connection with the tender
'/>"/>

SOURCE CV Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 Immunomic Therapeutics, Inc. announced today ... grant to support the continued preclinical development of a ... approximately $255,000 over one year to conduct vaccine validation ... allergy, affect over one million Americans and are the ... nut exposure is also a risk for peanut allergics, ...
(Date:9/17/2014)... 2014 Intarcia Therapeutics, Inc. today ... study of the cost and predictability of non-adherence in ... Annual Meeting of the European Association for the Study ... Christian Frois , Ph.D., of Analysis Group, Inc. presented ... Intarcia-sponsored, retrospective studies to characterize the prevalence of non-adherence ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014 Alternative Fuels ... agreement to form a Special Purpose Vehicle in partnership with ... Jatropha centric agro energy company. The SPV shall be called ... entity with AFAI as majority shareholder. The SPV shall pursue ... , particularly Ethiopia . ...
(Date:9/17/2014)... 17, 2014 Veracyte, Inc. (Nasdaq: ... the field of molecular cytology, today announced the promotion ... Mr. Hall joined Veracyte in 2010 as chief ... endocrinology. Since 2012, he has led sales, marketing, laboratory ... and billing functions. As chief operating officer, Mr. Hall ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... ... Local Needs for Increased Food Production , ... Des Moines, Iowa (Vocus) September 17, 2009 -- DuPont announced ... at three existing facilities to develop seed to meet local needs for food productivity. ...
... ... and came out as a beta. In this relaunch they have focused on do it more ... results. They have tried to get the users to get and give a personal experience. They ... ...
... , SCOTTSDALE, Ariz., Sept. ... knowledge for oncologists seeking therapy options for challenging patient ... free portal, Oncocentric.com. MedTrust Online also announced today ... Online,s growing board of oncology advisors. , , ...
Cached Biology Technology:DuPont Accelerating Rate of Productivity Through Additional Plant Breeding 2ePDF is Happy to Announce that ePDF has Completed its First Relaunch, and has Come Out as a Beta 2MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board 2
(Date:9/17/2014)... State,s Institute for the Arts and Humanities has received ... for a two-year project, "The Boundaries of the Human ... project will support a wide-ranging series of events aimed ... humanities. One involves artists and researchers who are exploring ... the idea of humanism, and the other involves the ...
(Date:9/17/2014)... Calif. (Sept. 17, 2014) A rare genetic disorder known ... to a recent joint investigation by researchers at San ... Diego. In addition to suggesting better treatment options for ... clues into the genetic underpinnings of autism., Jacobsen syndrome ... National Institutes of Health. It occurs in a person ...
(Date:9/17/2014)... Social Evolution and Yale University offers compelling support for ... can partially predict the likelihood of being diagnosed with ... in life. The study analyzed medical records of 1.75 ... to 30 years, and adjusted for almost all other ... the Proceedings of the Royal Society, London B ...
Breaking Biology News(10 mins):Mellon Foundation awards grant for major project in the humanities and sciences 2A link between Jacobsen syndrome and autism 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... gallery for Princeton University,s third Art of Science competition will ... site that allows members of the public to choose their ... the same time. The juried show features 48 works ... can be found here: www.princeton.edu/artofscience/2009 The ...
... new study has revealed that mother birds can provide ... sired with their non-social partner (known as extra-pair offspring). ... birds commonly mate with males other than their social ... interloper,s ,extra pair, offspring often outperform their half brothers ...
... dry periods are not only the result of severe drought. ... der Werf, has analyzed the density of smog during forest ... forest fires is directly linked to population density and land ... research on Feb. 22. The biggest problem of ...
Cached Biology News:Exhibition showcases the 'art of science' 2Exhibition showcases the 'art of science' 3Mothers give interloper's offspring a head start in life 2Mothers give interloper's offspring a head start in life 3Human role in Indonesian polluting forest fires -- Guido van der Werf in Nature Geoscience 2